FAX NO. 17818394121

P. 01

10/551259



Fax

To Alvarado M. Winston PCT Office of PCT Operations United States Patent and TradeMark Office

John X. Haberman/Global Intellectual Property, Patents

Copies

Subject

US Application No.: 10/551,259

Fax number 571 270 9878

Fax number +1 781 839 4736

September 11, 2007

Total pages

8

Reference Our Ref 100995-1P US

Dear Sir

Please find attached the Preliminary Amendment for US Application No.: 10/551,259 as requested from your telephone conversation of September 10, 2007.

Yours faithfully

John X. Haberman **Patent Attorney** 

**Encs** 

This message, including any attachments, is confidential, intended only for the recipient, and may be a confidential attorney client communication or may otherwise be privileged and confidential and protected from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, please be aware that any dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by replying to the message and deleting it from your computer, Thank you.

AstraZeneca Global Intellectual Property 35 Gatehouse Drive Maltham MA 02451-1215

Tel: +01 781 839-4000 Fax: +01 781 839-4121

www.astrazeneca-us.com


AstraZeneca R&D Boston 35 Gatehouse Drive Waltham, Massachusetts 02451-1215

H

	U			igh 07/31/2005, OMB 0651-0031 DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995.	no person: are required to respond to a Application Number	10/551,259	IVIGRA II DIZD	RVS B VAIIG OWIG CONTEST
	Filing Date	10/001,200		
TRANSMITTAL	First Named Inventor	09/27/2005 Beth Andrews		
FORM	Art Unit			
	Examiner Name	1655		
(to be used for all correspondence after initial f	(Ham)	Not yet know		
Total Number of Pages in This Submission	7 Attorney Docket Numb	100995-1P U	<u> </u>	
TOWN NOTICE OF THE PROPERTY OF	ENCLOSURES (Chec	k all that apply)		To To
Fee Transmittal Form  Fee Attached  X Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application	Drawing(s)  Licensing-related Papers  Petition Petition to Convert to a Provisional Application Power of Attorney, Revo Change of Corresponde Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table  Remarks	ocation nice Address	Appeal Coof Appeal Coopeal Coopeal Notes Income Inc	wance Communication to TC ommunication to Board is and interferences communication to TC lotice, Brief, Reply Brief) bry Information etter aclosure(s) (please identify
Reply to Missing Parts under 37 CFR 1.52 or 1.53	APPLICABLE A	TTOPNEY OR A	GENT	
	ATURE OF APPLICANT, A	TORRETTORA		
Firm Name AstraZeneca				
Signature 1.1 × 17	X			
Printed name John X. Haberman				
Date 09/11/0		Reg. No. 55,	236	
I hereby certify that this correspondence is sufficient postage as first class mail in an the date shown below:	CERTII-ICATE OF TRANS s being facelmite transmitted to the envelope addressed to: Commissi		445 ALA 11m	ited States Postal Service with Alexandria, VA 22313-1450 on
Signature				
Typed or printed name Audrey W	Illiams		Date	09/11/2007
Typed or printed name Audrey W	IIIIailis			The state of the s

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including processing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, proparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, proparing. The information officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer, U.S. Patent and 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/551,259	Applicant: Andrews et al
Filing Date: 09/27/2005	Attorney Docket No.: 100995-1P US
Examiner: Not yet known	Group Art Unit: 1655
Customer No.: 44992	Confirmation No.: 3367
Title: TOPOISOMERASE MOLULAT	TOR ASSAYS
Title: TOPOISOMERASE MOLICEA	TON ABONTO

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on Sciptember 11, 2007

Audrey Williams

Mail Stop Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## PRELIMINARY AMENDMENT

Prior to calculation of the claim fees and examination of the application on its merits, please amend it as follows:

Amendments to the claims begin on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.